Navigation Links
Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:7/24/2008

ns and symptoms of acute agitation. In March 2007, Alexza announced positive initial results from a multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial in 129 patients in an in-patient clinical setting. The 10 mg dose of AZ-004 met the primary endpoint of the clinical trial, which was a statistically significant reduction in the measure of agitation from baseline to the 2-hour post-dose time point, as compared to placebo. The 10 mg dose of AZ-004 also exhibited a rapid onset of effect, with a statistically significant improvement in the PEC scores at 20 minutes post-dose, as compared to placebo. The effectiveness of the AZ-004 10 mg dose was sustained throughout the 24-hour study period, as compared to placebo.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and completed the enrollment of its first Phase 3 clinical trial in June 2008. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
2. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
3. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
7. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
8. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
11. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Gen-Probe invests US$5 million in DiagnoCure SAN DIEGO and ... GPRO ) and DiagnoCure Inc. (TSX: CUR) today ... their 2003 license agreement, establishing new FDA submission milestones ... potential of the PCA3-based test for prostate cancer in ...
... 29 The recent announcement of the REDUCE trial results ... optimism to the prostate cancer community as dutasteride (Avodart), a ... lower by 23 percent the risk of prostate cancer in ... Network looks forward to this becoming an additional tool in ...
Cached Medicine Technology:Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 2Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 3Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 4Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 5Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer 2
(Date:4/17/2014)... By discovering a new mechanism that allows blood ... at UC Irvine and the Salk Institute have opened ... prevent stroke-induced brain damage. , A complex and devastating ... and primary reason for disability in the U.S. The ... lets blood-borne material into the brain, causing the permanent ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
(Date:4/17/2014)... 2014While 94 per cent of Canadians surveyed said they ... for a specific number of genetic conditions, only 80 ... in screening that would sequence their newborns, genomes.,Most newborns ... their first day or two of life in which ... heels and tested for about five to 54 conditions, ...
(Date:4/17/2014)... for more research to be carried out into ... Africa. In a paper in The Lancet ... with colleagues in the department of Parasitology and ... Ohio, University of Cambridge and the Royal Veterinary ... burden of HIV/AIDS and schistosomiasis of children, and ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2
... rheumatoid arthritis (RA), an autoimmune disease marked by chronic ... and the incidence of cancer is complicated. Epidemiologic ... cancers are increased among RA patients, while breast and ... are caused by the nature of RA or by ...
... for downward social mobility, study confirms , , TUESDAY, Aug. ... a downscale neighborhood often go together, a new study ... comes first. , "The more alcohol problems a man ... in, or migrate into, a disadvantaged neighborhood," according to ...
... report cites drop in employer-sponsored coverage , , TUESDAY, ... Americans are without health insurance, according to new U.S. ... trend can be explained by employers who are curtailing ... workers to afford, the report said. , "The number ...
... better diagnoses and therapies, researchers say , , TUESDAY, Aug. ... the brains of multiple sclerosis patients may help predict ... researchers are reporting. , "This is a new ... the tissue of the patient,s lesions," said lead researcher ...
... age 7 were virtually erased, study finds , , TUESDAY, ... during pregnancy and don,t get treatment, their kids face ... suggests that treatment can essentially eliminate that risk. , ... obesity can be completely reversed in these children, said ...
... to be published in an upcoming edition of ... that Pycnogenol (pic-noj-en-all), pine bark extract from the ... as hot flashes, depression, panic attacks, cholesterol and ... transition. The results suggest Pycnogenol may serve as ...
Cached Medicine News:Health News:Biologic treatment for rheumatoid arthritis and the risk of cancer 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 3Health News:Record Number of Americans Lack Health Insurance 2Health News:Record Number of Americans Lack Health Insurance 3Health News:Record Number of Americans Lack Health Insurance 4Health News:Brain Lesions Predict MS Progression 2Health News:Brain Lesions Predict MS Progression 3Health News:Treating Diabetes During Pregnancy Could Lead to Thinner Kids 2Health News:New study: Pine bark reduces perimenopausal symptoms 2
Cold light source dual outlet....
The 9100 is a truly affordable 100 Watt xenon light source providing accurate color and brightness. This xenon light source is ideal for surgery centers, evaluations or general office use....
... the brightest and most versatile light source ... 300 Watts, this unique light source allows ... an illuminated instrument or two UltraLite Headlights ... delivers bright, white light that is as ...
Loupe KS is achieved by a special system carrier....
Medicine Products: